Summary
Following an application from Specialised Nutrition Europe (SNE, formerly IDACE), submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to vitamin C and protection of DNA, proteins and lipids from oxidative damage.
The scope of the application was proposed to fall under a health claim referring to children's development and health.
The general approach of the NDA Panel for the evaluation of health claims applications is outlined in the EFSA general guidance for stakeholders on health claim applications and the guidance on the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health.
The food constituent that is the subject of the health claim is vitamin C, which is an essential nutrient and can be measured in foods by established methods. The Panel considers that vitamin C is sufficiently characterised.
The claimed effect proposed by the applicant is 'protection of cells due to its antioxidant activity'. The target population proposed by the applicant is infants (from birth) and young children up to 3 years of age. The Panel considers that protection of DNA, proteins and lipids from oxidative damage is a beneficial physiological effect.
The Panel has previously assessed a claim on vitamin C and protection of DNA, proteins and lipids from oxidative damage with a favourable outcome. The target population was the general population. The Panel considers that the role of vitamin C in protection of DNA, proteins and lipids from oxidative damage applies to all ages, including infants and young children up to 3 years of age.
The Panel concludes that a cause and effect relationship has been established between the dietary intake of vitamin C and protection of DNA, proteins and lipids from oxidative damage.
The following wording reflects the scientific evidence: 'Vitamin C contributes to the protection of cell constituents from oxidative damage'.
Vitamin C and protection from oxidative damage harmonises the provisions that relate to nutrition and health claims, and establishes rules governing the Community authorisation of health claims made on foods. As a rule, health claims are prohibited unless they comply with the general and specific requirements of this Regulation, are authorised in accordance with this Regulation, and are included in the lists of authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14-17 of this Regulation lay down provisions for the authorisation and subsequent inclusion of reduction in disease risk claims and claims referring to children's development and health in a Community list of permitted claims.
According to this Regulation, an application shall be submitted by the applicant to the national competent authority of a Member State, which will make the application and any supplementary information supplied by the applicant available to the European Food Safety Authority (EFSA).
Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion on the scientific substantiation of a health claim related to: vitamin C and protection of DNA, proteins and lipids from oxidative damage.
The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing of vitamin C, a positive assessment of its safety, nor a decision on whether vitamin C is, or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework of Regulation (EC) No 1924 No /2006 It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation procedure foreseen in Article 17 of Regulation (EC) No 1924/2006.
Additional information
A health claim on vitamin C and protection of DNA, proteins and lipids from oxidative damage has already been assessed by the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) with a favourable outcome (EFSA NDA Panel, 2009).
2.
Data and methodologies 2.1. Data 2.1.1. Information provided by the applicant 2.1.1.1. Food/constituent as stated by the applicant According to the applicant, the food constituent that is the subject of the claim is vitamin C.
Health relationship as claimed by the applicant
According to the applicant, vitamin C 'protects cells due to its antioxidant activity'. The applicant stated that vitamin C is an essential nutrient and a key element for the metabolism of almost all living organisms. An appropriate intake of vitamin C protects cells and DNA from oxidative damage.
Wording of the health claim as proposed by the applicant
The applicant has proposed the following wording for the health claim: 'Vitamin C protects cells due to its antioxidant activity'. The alternative wordings are 'ascorbic acid supports healthy cells by scavenging free radicals'.
Specific conditions of use as proposed by the applicant
The target population proposed by the applicant is infants and young children from birth to 3 years of age.
According to the applicant, the quantities needed to achieve the claimed effects are as follows:
• 
Data provided by the applicant
Health claim application on vitamin C and protection of cells from oxidative damage pursuant to Article 14 of Regulation 1924/2006 was presented in a common and structured format as outlined in the Scientific and technical guidance for the preparation and presentation of applications for authorisation of health claims (EFSA NDA Panel, 2011a).
As outlined in the General guidance for stakeholders on health claim applications, it is the responsibility of the applicant to provide the totality of the available evidence (EFSA NDA Panel, 2016).
Methodologies
The general approach of the NDA Panel for the evaluation of health claim applications is outlined in the EFSA general guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016).
The scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health are outlined in a specific EFSA guidance (EFSA NDA Panel, 2011b).
Assessment

Characterisation of the food/constituent
The food constituent that is the subject of the health claims is vitamin C (L-ascorbic acid, ascorbate), which is an essential nutrient and can be measured in foods by established methods.
Vitamin C is authorised for addition to foods (Annex I of Regulation ( The Panel considers that the food constituent, vitamin C, which is the subject of the health claim, is sufficiently characterised.
Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is 'protection of cells due to its antioxidant activity'. The target population proposed by the applicant is infants (from birth) and young children up to 3 years of age.
From the information provided, the Panel notes that the claimed effect refers to protection of DNA, proteins and lipids from oxidative damage.
The Panel considers that protection of DNA, proteins and lipids from oxidative damage is a beneficial physiological effect.
3.3.
Scientific substantiation of the claimed effect
The Panel has previously assessed a claim on vitamin C and protection of DNA, proteins and lipids from oxidative damage with a favourable outcome (EFSA NDA Panel, 2009 ). The target population was the general population. The Panel considered that vitamin C plays a role in protection of DNA, proteins and lipids from oxidative damage.
Vitamin C acts physiologically as a water-soluble antioxidant and plays a major role as a free radical scavenger (Sadler et al., 1999; IoM, 2000) . Vitamin C is part of the antioxidant defence system, which is a complex network including endogenous antioxidants and dietary antioxidants, antioxidant enzymes and repair mechanisms, with mutual interactions and synergetic effects among the various components.
The Panel considers that the role of vitamin C in protection of DNA, proteins and lipids from oxidative damage applies to all ages, including infants and young children (from birth to 3 years of age).
Panel's comments on the proposed wording
The Panel considers that the following wording reflects the scientific evidence: 'Vitamin C contributes to the protection of cell constituents from oxidative damage'.
Conditions and restrictions of use
The Panel considers that in order to bear the claim:
• Follow-on formulae should comply with the criteria for the composition of follow-on formulae as laid down in Directive 2006/141/EC.
• Nutritionally complete foods for special medical purposes intended for use by infants and nutritionally complete foods for special medical purposes other than those intended for use by infants should comply with the criteria for the composition of these foods as laid down in Directive 1999/21/EC. • The target population is infants and young children up to 3 years of age. EFSA did not set tolerable upper intake level (UL) for vitamin C (EFSA, 2004) .
Conclusions
On the basis of the data presented, the Panel concludes that:
• The food/constituent, vitamin C, which is the subject of the health claim, is sufficiently characterised.
• The claimed effect proposed by the applicant is 'protection of cells due to its antioxidant activity'. The target population proposed by the applicant is infants and young children from birth to 3 years of age. Protection of DNA, proteins and lipids from oxidative damage is a beneficial physiological effect.
• A cause and effect relationship has been established between the dietary intake of vitamin C and protection of DNA, proteins and lipids from oxidative damage.
• The following wording reflects the scientific evidence: 'Vitamin C contributes to the protection of cell constituents from oxidative damage'.
• In order to bear the claim, follow-on formulae should comply with the criteria for the composition of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally complete foods for special medical purposes intended for use by infants and nutritionally complete foods for special medical purposes other than those intended for use by infants should comply with the criteria for the composition of these foods as laid down in Directive 3) The scope of the application was proposed to fall under a health claim referring to children's development and health. 4) On 26/3/2008, during the validation process of the application, EFSA sent a request to the applicant to provide missing information. 5) On 10/7/2016, EFSA received the missing information as submitted by the applicant. 6) The scientific evaluation procedure started on 07/9/2016. 7) During its meeting on 13/12/2016, the NDA Panel, having evaluated the data, adopted an opinion on the scientific substantiation of a health claim related to vitamin C and protection of DNA, proteins and lipids from oxidative damage.
